Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
A long-acting GHRH analog usually paired with ipamorelin — with FDA-flagged safety concerns worth knowing before you consider it.
CJC-1295 is almost always discussed as half of a stack, not on its own. It deserves its own honest look — including a safety flag the FDA specifically called out.
A note on regulatory status (as of July 2026): CJC-1295 followed the same path as ipamorelin — Category 2 in 2023, back to Category 1 as of April 2026. Importantly, the FDA has specifically flagged CJC-1295 for limited clinical data and reports of serious adverse events, including increased heart rate and a systemic vasodilatory reaction. That's a more specific safety flag than most compounds on this page carry, and worth discussing directly with a provider.
CJC-1295 is a modified, longer-acting version of GHRH (growth-hormone-releasing hormone) — sometimes formulated with a chemical modification (DAC) that extends its activity in the body from minutes to days. Like the other growth-hormone secretagogues on this page, it has never completed FDA trials as a standalone approved drug.
CJC-1295 binds GHRH receptors in the pituitary, prompting growth hormone release the same way tesamorelin and sermorelin do — its differentiator is duration of action, not a different mechanism. The DAC-modified version is engineered to stay active for days rather than hours, which changes dosing frequency but also changes how sustained the resulting GH elevation is.
The GHRH mechanism itself is well established in the broader research literature. Evidence specific to CJC-1295's clinical outcomes and long-term safety in humans is limited — which is exactly what the FDA's own compounding review flagged when evaluating it.
Beyond the general injection-site reactions and flushing common to this class, the FDA-flagged adverse events — elevated heart rate and vasodilatory reactions — are a specific reason this compound needs cardiovascular screening before starting, not just general lab work. It's not appropriate for anyone with unevaluated cardiovascular symptoms or active malignancy.
CJC-1295's long duration of action is its main selling point — and also the reason its FDA-flagged cardiovascular signal deserves more attention than it typically gets in casual "stack" discussions. This is not a compound to combine with anything without a provider actively screening for that specific risk.
Regulatory status as of 2026-07-20.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense CJC-1295 or any medication.